Kornimate/medical-research-clean huggingface dataset:
lifestyle interventions for generalized anxiety disorder

Conditions: Aerobic Exercise; Stretching

Summary: this two-site (southern methodist university (smu) and boston university (bu)) study aims to examine the effectiveness of exercise interventions for the treatment of generalized anxiety disorder (gad). if effective, the use of exercise as a component of treatment for gad would have a significant public health impact. in addition to improving gad treatment outcome, exercise is expected to offer health benefits and promote further lifestyle changes. the present study involves the randomization of 52 adults with gad to either a 12-week combined supervised- home-based moderate-intensity aerobic exercise protocol (ex) or a 12-week combined supervised- home-based stretching protocol (ctrl). the investigators hypothesize that participants in the ex intervention will evidence greater improvements in anxiety symptoms and quality of life relative to individuals receiving the control intervention.


Eligibility criteria:
inclusion criteria: * male and female participants, ages 18-65. * principal diagnosis of generalized anxiety disorder. * willing to and capable of providing informed consent, attending all study visits, and complying with the protocol. * classified as either being at low risk or moderate risk for cardiovascular disease according to american college of sports medicine (acsm) risk stratification guidelines (see "telephone prescreen and risk stratification" section for more information). * sedentary as defined by acsm guidelines as not participating in at least 30 minutes of moderate-intensity exercise on at least 3 days a week for at least 3 months. exclusion criteria: * currently suicidal or high suicide risk, current or past psychotic disorders of any type, bipolar disorder (i, ii, or nos), schizophrenia or schizoaffective disorder, anorexia, bulimia. alcohol or drug dependence, abuse of depressants, dissociative anesthetics, hallucinogens, opioids, and cocaine within the last 6 months. comorbid psychiatric conditions that are relative or absolute contraindications to the use of any treatment option in the protocol. * cognitive behavioral therapy within three months of baseline, or ongoing supportive therapy directed specifically toward the treatment of anxiety or mood disorder. * psychotropic medications are acceptable only if they are stabilized for at least 3 weeks prior to the baseline visit, as long they are not considered a relative or absolute contraindication to the use of any treatment option in the protocol. * for women, currently pregnant, plans to be pregnant in the next year, or currently breastfeeding. * insufficient command of the english language (i.e., they cannot carry on a conversation with an interviewer in the english language or read associated text).
validation of medication non-adherence model (uk)

Conditions: Diabetes Mellitus; Chronic Obstructive Pulmonary Disease; Chronic Illness; Primary Care; Medication Management at Home

Summary: research has shown that nearly 50% of patients with chronic conditions around the globe do not adhere to their prescribed medicine, leading to enormous cost to the healthcare providers. non-adherence can be due to various forms and have multiple causes. to address this need, philips research has developed medication non-adherence model. this tool will help in developing a systemic way of assessing medication non-adherence and providing decision support for targeted intervention to healthcare professionals. the aim of this study is to validate this model with 750 chronically ill patients in uk.


Eligibility criteria:
inclusion criteria: * patients with chronic disease between 18 -89 years old. * chronic medication use (\> 3 medications; excluding analgesic, ointment and eye drop medication) * patients registered with a given pharmacy at least 1 year before entering into the study. exclusion criteria: * patients who are illiterate in english. * patients who are unable to give consent to the study. * enrolled in another clinical trial, which requires change in their routinely medication. * patients currently using automatic medication reminder services (excluding the pharmacy service). * patients with dementia or any other mental conditions, that might affects the accuracy of the answers provided.
a study to evaluate the tolerability, safety and pharmacokinetic characteristics of da-3803

Conditions: Infertility; Induction of Ovulation

Summary: this is a single-blind, randomized, comparative, phase i study to evaluate the tolerability, safety and pharmacokinetic characteristics of human chorionic gonadotropin between two recombinant hcg products named da-3803 injection and ovidrel liquid injection, in healthy subjects. the subjects will injected with these two injections at the the 21day-interval of time and their conditions including vital signs, blood, clinical examination will be carefully observed.


Eligibility criteria:
inclusion criteria: * no medical history relating to the alimentary system, liver system, heart system, haematological disease * ideal body weight +/- 20% exclusion criteria: * acute disease within 28 days * medical history that might affect the absorption, distribution, secretion, metabolism of drugs * metrectomy surgery * desexualization * tubal ligation * menopause * pregnancy * not able to use contraception * drink alcohol more than 14 units/week * smoker who smokes 10 or more cigarettes
a randomized study of spk-10001 gene therapy in participants with huntington's disease

Conditions: Huntington Disease

Summary: the main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of spk-10001 in participants with huntington's disease.


Eligibility criteria:
key inclusion criteria: * have confirmed huntingtin (htt) cytosine-adenine-guanine (cag) repeat length ≥40 on genetic testing and confirmation diagnostic test by the central laboratory (cl) at screening. * have striatal atrophy demonstrated by caudate/intracranial volume less than the age-adjusted cutoff values associated with hdiss stage 1. * have uhdrs total motor score (tms) equal to or greater than the age-adjusted cutoff value associated with hdiss stage 2. * have uhdrs total functional capacity (tfc) greater than or equal to 11. * use of cholinesterase inhibitors, memantine, amantadine, or riluzole must have been at stable dosing for at least 12 weeks before screening and baseline and anticipated to remain stable during the first 12 months after spk-10001 administration. * antidepressant or benzodiazepine use must have been at stable dosing for at least 12 weeks before screening and baseline and anticipated to remain stable during the first 12 months after spk-10001 administration. * antipsychotics for motor symptoms or mood stabilization (i.e., irritability or aggressive behavior) and/or tetrabenazine, valbenazine, or deutetrabenazine must have been at a stable dose for at least 12 weeks before screening and baseline and are anticipated to remain stable during the first 12 months after spk-10001 administration. key exclusion criteria: * a safe trajectory is not able to be identified for targeting placement of the cannula into the caudate or putamen on both sides of the brain due to extent of atrophy or other anatomical features. * have received an antisense oligonucleotide therapy during the past year. * history of deep brain stimulation. * history of or intention to undergo gene therapy, cell transplantation, or brain surgery during the course of the study. * have participated in an investigational drug study with a systemic administration within 6 weeks or 5 half-lives of screening, whichever is longer. additional protocol-defined inclusion/exclusion criteria apply.

Keywords: huntington's disease spk-10001 adult-onset hd hd rare disease chorea movement disorder spark therapeutics cognition gene therapy aav mhtt
individualized elective neck irradiation in npc patients

Conditions: Nasopharyngeal Carcinoma

Summary: to evaluate whether individualized elective neck irradiation for nasopharyngeal carcinoma based on the vertebral level of metastatic lymph nodes can reduce the incidence of radiation-related adverse effects and improve patients' quality of life，without reducing survival.

a multicenter phase iii noninferiority randomized trial (nct02642107) showed that upper-neck irradiation at the uninvolved neck resulted in comparable regional control and survival rate to standard whole-neck irradiation in npc, reduced late toxicity of hypothyroidism, dysphagia, and neck tissue damage, and improved quality of life, including fatigue and swallowing. however, the vertical range of the upper neck is extensive, necessitating further reduction in the scope of prophylactic irradiation. by integrating mri and pet-ct to accurately assess metastatic lymph nodes and their corresponding vertebral levels, the investigators identified a pattern of sequential lymph node metastasis descending along the vertebral body in the vertical direction. further correlative analysis revealed that nodal metastasis at any one of the vertebral levels strongly and positively correlated with metastasis at two adjacent vertebral levels, including one level above and one below. considering this, the investigators propose the following scientific hypothesis: individualized elective neck irradiation for nasopharyngeal carcinoma based on the vertebral level of metastatic lymph nodes can reduce the incidence of radiation-related adverse effects and improve patients' quality of life, without reducing survival. the investigators thus conduct a multicenter randomized phase 3 trial to verify their hypothesis.

Eligibility criteria:
inclusion criteria: * the eligibility criteria are: newly diagnosed, untreated, non-distant metastatic, and non-keratinizing npc; nodes are diagnosed with pet/ct and mri; staged as t1-4n0-2 or n3 category of non-bilateral lower node metastasis; aged between 18 and 70 years; karnofsky performance-status score \> 70; adequate haematological function, with a leucocyte count \> 4 × 109/l, haemoglobin \> 90 g/l, and a thrombocyte count \> 100×109/l exclusion criteria: * the exclusion criteria include: previous chemotherapy treatment, surgery (except diagnostic) or radiotherapy to the neck or nasopharyngeal regions; previous malignancy; lactation or pregnancy; or severe coexisting illness.
comparative effectiveness of endoscopic assessment of gastroesophageal reflux and barretts esophagus

Conditions: Barrett's Esophagus

Summary: the hypothesis of this study was that the comparative effectiveness of unsedated transnasal endoscopy (utne) will be greater than sedated endoscopy (segd) in population screening for be.

barrett's esophagus (be), a well-known complication of gastroesophageal reflux (ger), is the strongest known precursor of esophageal adenocarcinoma. thus, identifying effective screening approaches for the early detection of be are highly desired. current impediments to be screening include 1) the inability to utilize sedated endoscopy (segd) effectively in populations and 2) current ger-based paradigms for detecting be. referral center studies demonstrate comparable accuracy between unsedated transnasal endoscopy (utne) and segd. however, patient acceptability and diagnostic yield with utne in general populations remain unknown. using the rochester, minnesota epidemiology project resources, random samples of olmsted county residents were drawn, and those subjects were mailed validated gastrointestinal symptom questionnaires. these surveys allowed identification of a cohort of community subjects well characterized by the frequency of reflux symptoms. eligible subjects who were greater than or equal to 50 years old, and who had no previous history of endoscopic evaluation and who were not known to have be were randomized, stratified by age, sex, and reflux symptoms, and assigned to one of the 3 arms of the study. subjects in each arm who met the eligibility criteria were initially sent generic invitation letters asking if they agreed to be contacted by phone in two weeks' time to inform them about a research study. if potential subjects explicitly declined to be contacted they were excluded from the study. eligible subjects were contacted by telephone and only offered the endoscopy technique they had been randomized to. subjects who accepted and signed an informed consent document were treated according to their randomized assignment and all 3 groups were followed up in the same manner. biopsies were taken from any endoscopically suspected be and from the gastroesophageal junction and squamous mucosa in all subjects. the length of be segment was defined using prague criteria. all participants received a telephone call from the research coordinator 1 and 30 days after the procedure to complete validated tolerability scales and adverse events questionnaires.

Eligibility criteria:
inclusion criteria: * olmsted county, minnesota resident * age 50 or older * able to give informed consent exclusion criteria: * history of known barretts esophagus (be) or endoscopy within the last 10 years * history of progressive dysphagia * known zenkers or epiphrenic diverticulum * history of recurrent epistaxis * illnesses that impair ability to complete questionnaires (e.g. metastatic cancer, stroke, dementia) * contraindication to esophageal biopsy (such as anticoagulation using warfarin or clopidogrel).

Keywords: barrett's esophagus
analysis of change of optic nerve sheath diameter in in patients operated for urological reasons

Conditions: Anaesthetic Complication Neurological; Central Nervous System Depression

Summary: the assessment of the diameter of the optic nerve sheath (onsd) using ultrasound can be a very helpful tool in the assessment of increased intracranial pressure in patients operated for urological procedures.

advantages of using ultrasound in the assessment of intracranial pressure: simple, bedside examination, repetitive, generally available, cheap, no exposure to x-rays, no need to transport the patient to the ct laboratory differential diagnosis: widening of the size of the optic nerve sheath outside of increased intracranial pressure may occur in the following pathologies: optic neuritis optic nerve injuries meningioma of the optic nerve arachnoid cyst around the optic nerve tumors of the cavernous sinus blood edema may occur due to impaired blood flow. the research is to determine whether the patient's position for urological procedures is safe for the patients and whether as a result of staying in such a position there is no development of cerebral edema.

Eligibility criteria:
inclusion criteria: * patients undergoing urologic operation * adults 18 to 90 years of age * american society of anesthesiologists physical grade 1-3 exclusion criteria: * patients who did not agree to participate in the study * patients with ophthalmic diseases * patients with previous history of ophthalmic surgery * patients with neurological disorders * patients with history of head surgery due to neurological disorders * patients with history of disease with increased intracranial pressure * patients with history of disease with increased intraocular pressure

Keywords: optic nerve sheath diameter urological anaesthesia point of care usg
evaluation of the dermal cooling system for treatment of common skin conditions

Conditions: Skin Lesion

Summary: the purpose of this study is to evaluate whether the dermal cooling system can be used to elicit an improvement in the cosmetic appearance or physical symptoms of common skin conditions.

this is a prospective, non-randomized, open-label study to evaluate the effectiveness of the dermal cooling system to determine if cosmetic benefits or physical symptoms are achieved in common skin conditions.

Eligibility criteria:
inclusion criteria: 1. male or female subjects \> 18 years of age. 2. subject has a skin condition amenable to cryosurgical treatment including, for example, psoriasis, atopic dermatitis, acne, rosacea, and melasma. 3. subject is willing to have skin exposed to cooling with the dermal cooling system. 4. subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes. 5. subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of spf 50 or higher on the treated area for the duration of the study, including the follow-up period, if requested. 6. subject has read and signed a written informed consent form. 7. subject is willing to comply with adjuvant topical regimen, as applicable. 8. subject agrees not to undergo any other procedure(s) in the treatment area during the study. exclusion criteria: 1. dermatological conditions (e.g. vitiligo, open wounds, infection, pre-cancerous or malignant lesions) in the location of the treatment sites that would, in the professional opinion of the investigator, potentially pose an increased risk to the subject 2. use of accutane within the previous 6 months 3. history of melanoma 4. subject is pregnant or intending to become pregnant during the study period 5. subject is lactating or has been lactating in the past 6 months 6. known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, reynaud's disease. 7. history of abnormal wound healing or abnormal scarring 8. inability or unwillingness to comply with the study requirements. 9. current enrollment in a clinical study of any other unapproved investigational drug or device. 10. any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
comparative efficacy of 10% potassium hydroxide solution versus cryotherapy in molluscum contagiosum

Conditions: Molluscum Contagiosum

Summary: a total of sixty patients presented to the outpatient dermatology department of combined military hospital (cmh) abbottabad with signs of molluscum contagiosum clinically diagnosed meeting inclusion criteria were enrolled. sample size was calculated using who sample size calculator. they were divided into two groups i.e group a and group b using lottery method. patients in group a were subjected to cryotherapy (liquid nitrogen gas) whereas patients in group b patients were subjected to 10% potassium hydroxide solution for 3 weeks and were followed up at 2nd, 4th, 8th and 12th week for observing the progress of therapy in both groups on each follow up visit and ascertaining the efficacy respectively.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of molluscum contagiosum having 3-20 lesion * no history of treatment before * willingness to participate (given by parents) exclusion criteria: * patients with facial lesions * known immunodeficiency * tendency for hypertrophic scarring * known hypersensitivity
safety and efficacy study of fabulous stent graft system for stanford b aortic dissection

Conditions: Aortic Dissection Type B

Summary: a prospective, multi-center, objective performance criteria clinical trial to evaluate the safety and efficacy of fabulous stent graft system manufactured by hangzhou endonom medtech co., ltd. for stanford b aortic dissection.


Eligibility criteria:
inclusion criteria: 1. patients ≥18 years old; 2. the informed consent was signed by the patient or the legal representative; 3. diagnosed with stanford b aortic dissection; 4. the proximal anchoring area of is 18-42 mm in diameter, and not less than 15mm in length; 5. has a suitable arterial approach and is suitable for surgical treatment. exclusion criteria: 1. the patient's distal vascular false cavity has been completely thrombotic or organized; 2. pregnant or breastfeeding ; 3. has participated in clinical trials of other devices ； 4. history of aortic surgery or endovascular repair surgery ; 5. allergic to contrast agents and anesthetics ; 6. allergic to stents or conveyors ; 7. patients with true or false aortic aneurysm; 8. history of myocardial infarction, tia or cerebral infarction within the past 3 months; 9. life expectancy is less than 12 months; 10. other situations in which the investigator judges that not suitable for endovascular treatment .
sleep habits and ami and gensini score

Conditions: Sleep Disorder; Acute Myocardial Infarction

Summary: this study was to examine the effects of sleep habits on acute myocardial infarction (ami) risk and severity of coronary artery disease (cad) in chinese population from two centers. a total of 873 patients were recruited from the inpatient cardiology department of the affiliated jiangning hospital and the first affiliated hospital of nanjing medical university. investigators used a 17-item sleep factors questionnaire (sfq) to evaluate sleep habits comprehensively by face-to-face interview.

growing evidence indicates that poor sleep harms health. early to bed and early to rise is considered as a healthy lifestyle in chinese population. the current study aimed to examine the effects of sleep habits on acute myocardial infarction (ami) risk and severity of coronary artery disease (cad) in chinese population from two centers. a total of 873 patients including 314 with ami were recruited from the inpatient cardiology department of the affiliated jiangning hospital and the first affiliated hospital of nanjing medical university. 559 controls included 395 cad cases and 164 non-cad cases. investigators used a 17-item sleep factors questionnaire (sfq) to evaluate sleep habits comprehensively by face-to-face interview. the severity of cad was assessed by gensini score in ami and cad groups. the effects of sleep factors on ami risk and gensini score were examined by unconditional logistic regression. the timing of sleep (24:00 and after), sleep duration (\<6h) and frequency of night-time waking (3 times) increased the risk of ami. in subjects with age ≤60 years, daytime napping reduced the risk of ami. the correlation between sleep quality and ami became insignificant after subgroup analysis by age. short sleep duration also increased the risk of high gensini score.

Eligibility criteria:
inclusion criteria: 1. underwent coronary angiography; 2. can complete sleep factors questionnaire. exclusion criteria: 1. mental diseases; 2. sleep apnea; 3. chronic obstructive pulmonary disease; 4. stroke sequelae; 5. arthritis; 6. renal failure; 7. tumor and a history of revascularization.

Keywords: sleep habits sleep duration daytime napping gensini score late sleeping